DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hutzler, J. M.
Right arrow Articles by Tracy, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hutzler, J. M.
Right arrow Articles by Tracy, T. S.

Vol. 30, Issue 11, 1194-1200, November 2002

Activation of CYP2C9-Mediated Metabolism by a Series of Dapsone Analogs: Kinetics and Structural Requirements

J. Matthew Hutzler, Dhanashri Kolwankar, Matthew A. Hummel, and Timothy S. Tracy

Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia

Cytochrome P450 2C9-mediated metabolism has been shown to be activated in the presence of the effector dapsone. However, it has yet to be established what effector structural features are necessary to activate CYP2C9 activity. To address this question, kinetic studies were conducted with nine analogs of dapsone containing various functional properties (three sulfone compounds, three carbonyl compounds, and three sulfonamide compounds), to examine the functional groups important for enzyme activation by the effector (dapsone). Results show that phenylsulfone (dapsone without the para-amino groups) activates flurbiprofen 4'-hydroxylation comparable to dapsone but inhibits naproxen demethylation. Meanwhile, p-tolylsulfone had little effect on flurbiprofen metabolism, but activated naproxen demethylation, albeit only at high concentrations. These substrate-dependent differences in effect suggest that naproxen has a different binding orientation compared with flurbiprofen. Perhaps most interesting is that replacement of only one amino group from dapsone with a nitro group (4-(4-nitrophenylsulfonyl)-aniline) resulted in substantial inhibition of flurbiprofen 4'-hydroxylation, suggesting that electronic effects may influence activation of this substrate. Other analogs either had minor or no effect on CYP2C9-mediated metabolism. Overall, it is apparent from these studies that a sulfone group in direct association with two benzene rings with para-electron-donating groups represents the most efficient activator of CYP2C9. However, the effects of these analogs appear to be concentration- and substrate-dependent, further complicating the prediction of these types of in vitro interactions.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
D. Si, Y. Wang, Y.-H. Zhou, Y. Guo, J. Wang, H. Zhou, Z.-S. Li, and J. P. Fawcett
Mechanism of CYP2C9 Inhibition by Flavones and Flavonols
Drug Metab. Dispos., March 1, 2009; 37(3): 629 - 634.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo Jr., et al.
N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES
Drug Metab. Dispos., May 1, 2006; 34(5): 748 - 755.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
M. A. Hummel, T. S. Tracy, J. M. Hutzler, J. L. Wahlstrom, Y. Zhou, and D. A. Rock
Influence of Fluorescent Probe Size and Cytochrome b5 on Drug-Drug Interactions in CYP2C9
J Biomol Screen, April 1, 2006; 11(3): 303 - 309.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
K.-H. Liu, M.-J. Kim, W. M. Jung, W. Kang, I.-J. Cha, and J.-G. Shin
LANSOPRAZOLE ENANTIOMER ACTIVATES HUMAN LIVER MICROSOMAL CYP2C9 CATALYTIC ACTIVITY IN A STEREOSPECIFIC AND SUBSTRATE-SPECIFIC MANNER
Drug Metab. Dispos., February 1, 2005; 33(2): 209 - 213.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
B. D. Marks, D. V. Thompson, T. A. Goossens, and O. V. Trubetskoy
High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid(R) Substrates
J Biomol Screen, August 1, 2004; 9(5): 439 - 449.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A.-C. Egnell, C. Eriksson, N. Albertson, B. Houston, and S. Boyer
Generation and Evaluation of a CYP2C9 Heteroactivation Pharmacophore
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 878 - 887.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. W. Locuson II, J. L. Wahlstrom, D. A. Rock, D. A. Rock, and J. P. Jones
A NEW CLASS OF CYP2C9 INHIBITORS: PROBING 2C9 SPECIFICITY WITH HIGH-AFFINITY BENZBROMARONE DERIVATIVES
Drug Metab. Dispos., July 1, 2003; 31(7): 967 - 971.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.